Sender Co & Partners Inc. Sells 59,324 Shares of Kenvue Inc. (NYSE:KVUE)

Sender Co & Partners Inc. reduced its stake in shares of Kenvue Inc. (NYSE:KVUE) by 69.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 25,566 shares of the company’s stock after selling 59,324 shares during the period. Kenvue makes up approximately 0.7% of Sender Co & Partners Inc.’s holdings, making the stock its 25th biggest holding. Sender Co & Partners Inc.’s holdings in Kenvue were worth $591,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. M&T Bank Corp lifted its stake in Kenvue by 4.6% in the 3rd quarter. M&T Bank Corp now owns 106,594 shares of the company’s stock valued at $2,465,000 after acquiring an additional 4,654 shares in the last quarter. LRI Investments LLC grew its stake in shares of Kenvue by 49.1% during the 3rd quarter. LRI Investments LLC now owns 19,232 shares of the company’s stock worth $454,000 after acquiring an additional 6,331 shares in the last quarter. Nomura Asset Management Co. Ltd. raised its holdings in shares of Kenvue by 2.6% in the third quarter. Nomura Asset Management Co. Ltd. now owns 4,344,726 shares of the company’s stock valued at $100,494,000 after purchasing an additional 110,929 shares during the last quarter. MML Investors Services LLC lifted its position in shares of Kenvue by 3.3% in the third quarter. MML Investors Services LLC now owns 179,130 shares of the company’s stock worth $4,143,000 after purchasing an additional 5,714 shares in the last quarter. Finally, XTX Topco Ltd boosted its holdings in Kenvue by 93.1% during the third quarter. XTX Topco Ltd now owns 79,233 shares of the company’s stock worth $1,833,000 after purchasing an additional 38,193 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

Kenvue stock opened at $22.81 on Tuesday. The company has a market capitalization of $43.73 billion, a price-to-earnings ratio of 41.47, a PEG ratio of 2.07 and a beta of 1.37. The stock’s 50 day moving average is $22.96 and its 200-day moving average is $21.13. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.27 by $0.01. The business had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. Kenvue’s revenue was down .4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.31 earnings per share. Equities research analysts expect that Kenvue Inc. will post 1.07 EPS for the current year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th were issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.59%. The ex-dividend date of this dividend was Wednesday, November 13th. Kenvue’s dividend payout ratio (DPR) is currently 149.09%.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. JPMorgan Chase & Co. lifted their price target on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Royal Bank of Canada downgraded Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 target price on the stock. in a research report on Tuesday, September 24th. Piper Sandler increased their price target on Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a research report on Monday, September 23rd. Jefferies Financial Group began coverage on Kenvue in a research report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price target on the stock. Finally, Bank of America increased their price objective on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.